Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Clinical Professor Peter K Panegyres MD PhD FRACP PREDICT-HD Neurosciences Unit Intervention model for HD Document natural history of premanifest HD Development of Markers Clinical Imaging Outcome measures Preventative Clinical Trials 32 sites International Observational Premanifest HD Annual examination 2001-2014 N=1013 participants (premanifest) N=301 negative control > 35 CAG expansion repeats = cases < 36 gene mutation negative = controls Median duration in study = 6 years (range 1-10) 75% sample > 3 years data 15% - 2 years <10% - 1 year N=204 gene expanded participants received a motor diagnosis = converters Dropout < 5% per year CAG-AGE product [CAP] score = CAPE = [age at entry] x [CAG -33.66] Estimate proximity to HD diagnosis CAPE can be used to estimate 5 year probability of motor diagnosis CAPE < 290 290 CAPE 368 > 368 [low] 12.78 years [medium] 7.59-12.78 yrs [high] < 7.59 years Change over time – controlling for covariates of age, gender, depressed mood, brain scanner field strength Comparison of premanifest and control LMER (linear mixed effects regression) 39 variables analysed separately Graphical analysis to represent phenotypic characteristics of HD: Motor, cognitive, psychiatric + Biological (imaging) + Functional outcomes Variables with largest effect sizes ◦ Regional brain volumes ◦ TMS [UHDRS], esp bradykinesia and chorea ◦ Decline in cognitive performance in every measrue examined, esp symbol digits modalities test ◦ Functional variables, every measure esp TFC ◦ Psychiatric variables, esp Obsessive compulsive scale Frontal systems behavioural scale executive and apathy scales Six variables significant acceleration of the slope of participants who converted: Dystonia Stroop FAS SDMT TFC TMS Estimated effect size for a two-arm Phase II randomised control trial Effect size 20% ◦ Required sample for say TMS = 981 Dropout rate 20% ◦ Sample required TMS = 1131 CSF space ◦ 20% effect ◦ 20% dropout = 332 = 386 Plots of key outcome variables for preventative clinical trials Data derived model for disease progression Longitudinal change in 36 of 39 measures over 10 years of natural observation study Effect sizes suggest a preventative RCT could be designed to detect treatment effects of 30% Significant measures ◦ Clinical phenotype HD – motor, cognitive, psychiatric ◦ Biological ◦ Functional Specific measure a disease state chosen The effects of ageing Real natural history data 1300 gene mutation tested individuals followed prospectively through actual motor diagnosis Phenotypic and biological changes decade prior to, and just after, manifestations of disease Biological progression in premanifest HD is ◦ Linear for imaging, cognitive and psychiatric ◦ Non-linear for motor and functional Motor expression accelerates as the disease manifests over 15 years prior to motor onset Worldwide collaboration Relevant to clinical trials Collection of CSF to analyse Huntingtin protein and other biomarkers as clues to disease progression • Patients and families • Huntington’s Study Group • PREDICT Team – Jane Paulsen & colleagues • Rachel Zombor, Mark Woodman, Elizabeth Vuletich, Steve Andrews, Maria Tedesco, Carmela Pestell • Staff at the Neurosciences Unit